x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

HCPLive Podcasts

Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.

health & fitness medicine

All Episodes

21:35

Advances in Pediatric Eczema Highlight 2022

HCPLive Podcasts ·

2022/12/21

Lawrence Eichenfield, MD, reviews major drug approvals and advancement of screening and prevention strategies for the youngest patients with atopic dermatitis.

en

13:18

What Ruxolitinib Cream Meant For Dermatology in 2022

HCPLive Podcasts ·

2022/12/20

As 2022 concludes, a dermatologist reflects on the first drug approved for vitiligo.

en

18:47

A Geographic Atrophy Treatment Breakthrough with...

HCPLive Podcasts ·

2022/11/10

Dr. Lally of New England Retina Consultants joins to discuss avacincaptad pegol, a promising injection treatment for GA, and its supporting data from the GATHER trial program. Will the complement C5 inhibitor drug receive FDA approval in 2023? Lally discusses this and more on the latest DocTalk.

en

13:04

ACR 22 Convergence Preview, with Dr. McMahan

HCPLive Podcasts ·

2022/11/07

Ahead of the American College of Rheumatology 2022 Convergence meeting on Nov. 10-14, our editorial team sat down with planning committee member Zsuzsanna McMahan, MD, MHS, of Johns Hopkins University School of Medicine, to take a deep dive into the upcoming meeting.

en

13:25

Rare Disease Report: The FDA Decision for Pompe...

HCPLive Podcasts ·

2022/10/28

The FDA is expected to announce the final decision for the dual therapy AT-GAA, which uses miglustat in combination with cipaglucosidase alfa for treating Pompe disease, an inherited and often times fatal disorder. Expert Barry Byrne discusses the characteristics of the condition and what this FDA decision will mean for treatment.

en

12:30

Arshad Khanani, MD: A Breakthrough in Geographic...

HCPLive Podcasts ·

2022/10/14

One of the most notable topics discussed at the 2022 American Academy of Ophthalmology Meeting in Chicago was new advancements in geographic atrophy (GA) treatment. A form of advanced age-related macular degeneration (AMD), there are no currently available treatments for the debilitating disease. In this episode of DocTalk, we spoke with Arshad Khanani, MD, Director of Clinical Research, Sierra Eye Associates, on the findings from the GATHER2 trial on avacincaptad pegol for the treatment of

en

20:46

Rare Disease Report: Newborn Screening Awareness &...

HCPLive Podcasts ·

2022/10/10

In the wake of Newborn Screening Awareness Month, this episode dives into a novel diagnostic precision medicine guidance tool called BeginNGS. Catherine Nester, RN, and Dr. Stephen Kingsmore, discuss the pivotal role of newborn screening in diagnosing rare diseases. As representatives from collaborating partners Inozyme Pharma and Rady Children's Institute that created this tool, they explain the impact that BeginNGS can have on the future of rare disease medicine.

en

23:31

Heart Team: Making Ground on Women's Cardiovascular...

HCPLive Podcasts ·

2022/10/05

Martha Gulati, MD, Director of Preventive Cardiology, Associate Director of the Barbara Streisand Women’s Heart Center, Associate Director of Preventive and Cardiac Rehabilitation at Cedars-Sinai Medical Center, joins Heart Team to discuss current challenges in women’s cardiovascular disease research and clinical advancement. Gulati also provides guidance on improving female trial enrollment strategies and patient recruitment, and her thoughts on clinician perception of cardiovascular symptoms in

en

24:13

Marla Dubinsky, MD: The Future of IIL-23 Treatments...

HCPLive Podcasts ·

2022/09/30

en

31:14

Heart Team: Cardiology & Nephrology Collaborations...

HCPLive Podcasts ·

2022/09/06

In the first episode from this new cardiovascular medicine series, hosts Dr. Jorge Plutzky and Dr. Michael Farkouh speak with University of Maryland's Dr. Matthew Weir about the growing involvement of renal care in modern heart disease patients.

en

19:05

Rare Disease Report: CDKL5 Deficiency Disorder Expert...

HCPLive Podcasts ·

2022/09/02

The second episode of the 2-part Rare Disease Report shifts to a clinical perspective with the expertise of Dr. Pestana, a pediatric epileptologist at the Epilepsy Center, Cleveland Clinic Neurological Institute who treats patients with CDKL5 deficiency disorder (CDD).

en

23:51

Rare Disease Report: CDKL5 Deficiency Disorder

HCPLive Podcasts ·

2022/08/31

In the first episode of a 2-part Rare Disease Report, Whitney Mitchell, mother and caregiver to her 6 year old daughter Havilah, shared her experience leading up to, and now living with, Havilah’s CDKL5 deficiency disorder (CDD) diagnosis.

en

17:29

John J. Miller, MD: A New Era For Psychiatric...

HCPLive Podcasts ·

2022/08/18

en

13:47

Nonprofit Research on Gene Therapy for Rare Ocular...

HCPLive Podcasts ·

2022/08/03

en

20:02

Bindu Anand Balani, MD: Eradicating Hepatitis C Virus...

HCPLive Podcasts ·

2022/07/28

en

13:46

The Biggest Discussions in Retina from the 2022 ASRS...

HCPLive Podcasts ·

2022/07/20

This past week, the American Society of Retina Specialists (ASRS) held its 40th Annual Meeting in New York City to discuss landmark data and the newest advancements in retina care. The HCPLive team was on-site at the Javits Center in Manhattan conducting interviews with expert retina specialists on topics including drugs for neovascular age-related macular degeneration and geographic atrophy, as well as landmark trials including the phase 3 TENAYA and LUCERNE. On this episode of DocTalk, we

en

8:13

FDA Approves Ruxolitinib: New Horizons in Vitiligo Care

HCPLive Podcasts ·

2022/07/20

On Monday, the US Food and Drug Administration (FDA) approved ruxolitinib cream 1.5% for the treatment of nonsegmental vitiligo in adults and pediatric patients 12 years and older, making it both the first FDA-approved therapy for repigmentation and the only topical formulation of a JAK inhibitor approved in the United States. The groundbreaking approval was supported by phase 3 data from the TRue-V clinical trial program, which found that roughly 3 in 10 patients who were treated with ruxolitinib

en

15:57

How Pegloticase Plus Methotrexate is Breaking Ground...

HCPLive Podcasts ·

2022/07/12

Last week, the US Food and Drug Administration (FDA) approved the co-treatment of pegloticase (Krystexxa) injection plus methotrexate (MTX) for uncontrolled gout, a decision bolstered by data from phase 4 of the MIRROR study. In that study, 71% of patients who were treated with this combination therapy achieved a complete response over the course of 6 months. Comparatively, only 38.5% of patients who received pelgoticase plus placebo achieved a complete response. In a then-recent statement, John

en

14:15

What Ustekinumab Provides in Long-Term IBD Care

HCPLive Podcasts ·

2022/06/29

Despite a bevy of biologics available for people struggling with Crohn’s disease and ulcerative colitis (UC), not all patients are able to respond to or tolerate a vast majority of approved therapies. Fortunately, new data presented at Digestive Disease Week (DDW) 2022 suggests that ustekinumab (STELARA) could function as an alternative option to bio-failure and bio-naïve patients living with these inflammatory bowel diseases (IBD). Pooled data from four long-term phase 2 and 3 studies of

en

9:13

Exploring New Horizons in Ophthalmology Care with...

HCPLive Podcasts ·

2022/06/27

If you’ve been keeping an eye on recent developments in ophthalmic care, then you’ll know that several new therapeutic agents that had been approved by the US Food and Drug Administration (FDA) in recent months, including ranibizumab delivered via Port Delivery System (PDS) and faricimab, the latter of which became the first-of-its-kind intravitreal bispecific biologic therapy for both age-related macular degeneration (AMD) and diabetic macular edema. But the recent advancements in ophthalmology

en

211 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown